6 results about "Digoxigenin" patented technology

The invention provides a novel SNP (Single Nucleotide Polymorphism) three-dimensional fluorescence in-situ hybridization detection probe and a detection method, and belongs to the technical field of gene detection, the probe comprises a hairpin structure and is composed of an annular sequence and a stem-loop sequence, 5'end and 3 'end chain segments of the stem-loop sequence are respectively modified with digoxin antigens, the digoxin antigens are combined with anti-digoxin antibodies with fluorescence report group clusters and quenching group clusters, and the digoxin antigens with fluorescence report group clusters and quenching group clusters are combined with digoxin antigens with fluorescence report group clusters and quenching group clusters. The tail end of the 3'end chain segment is connected with the primer through a non-reaction monomer. The detection method comprises the steps of sample collection and pretreatment, double-stranded nucleic acid melting, probe hybridization and signal generation, and fluorescence signal detection. The sensitivity is improved through multiple signal amplification, rapid detection is achieved without enzyme amplification, and the kit has high specificity, is easy and convenient to operate, high in cost benefit and wide in applicability and can be used for drug gene SNP detection and other scenes.

This invention relates to the field of chemical synthesis, specifically to a nucleotide analog, its preparation method, and its applications. The invention provides a nucleotide analog, its preparation method, and its applications. This nucleotide analog utilizes digoxigenin or biotin as a marker, achieving precise base recognition and high-sensitivity sequencing through binding to a specific enzyme system. Compared to currently widely used sequencing methods, it requires fewer copy numbers. Furthermore, G base quenching can be suppressed.

This invention relates to the field of biology, and particularly to a ligand-coupled microsphere for measuring inverse-locking levels, its preparation method, and a method for measuring inverse-locking levels. The ligand-coupled microsphere comprises a ligand coupled with a first label, a DNA fragment, and a polystyrene microsphere. A second label is coupled to one end of the DNA fragment, and the second label specifically binds to the first label. Digoxigenin is coupled to the other end of the DNA fragment. An anti-digoxigenin antibody is coupled to the surface of the polystyrene microsphere, and the polystyrene microsphere is linked to the DNA fragment via the anti-digoxigenin antibody and digoxigenin. The measurement method of this invention can measure different receptor-ligand interactions and enables its application in commercial instruments, forming a more universal inverse-locking measurement method. This allows inverse-locking measurements to be applied in more situations, providing theoretical support for the engineering modification of various receptors such as TCR, and providing data support for clinical applications.

The present invention belongs to the technical field of antibodies. Provided is an anti-digoxigenin antibody or an antigen-binding fragment thereof. The anti-digoxigenin antibody or antigen-binding fragment thereof has high affinity for digoxigenin; and can be used for detection of digoxigenin, sequencing, preparation of a product used for detecting digoxigenin, and preparation of a product used in sequencing.

The present invention relates to humanized antibodies having good binding ability to digoxigenin and uses thereof. When an antibody or antigen-binding fragment thereof specifically recognizing digoxigenin according to one aspect of the present invention is used, the concentration of the drug in the body is adjusted as needed through a complex (DOligobody) containing the same, or the concentration of the drug in vivo It is expected that the half-life can be increased.

The present invention relates to a novel proteasome inhibitor comprising a digoxigenin-derived lactone ring-based compound as an active ingredient, and can simultaneously exhibit high 20S proteasome inhibitory activity and low normal cell toxicity. The compound has excellent cancer cell selectivity, has pharmacological properties with improved anticancer effects and therapeutic indices, and can be useful for various carcinomas such as multiple myeloma, breast cancer, and hepatocellular carcinoma.